ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 024,39
0,39%
Dow Jones
38 686,32
1,51%
DAX
18 639,74
0,85%
Brent Oil
81,215
0,51%
Bitcoin
68 866,93
1,65%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Orchard Therapeutics PLC (ORTX)

  7. Orchard Therapeutics PLC (ORTX) Actualités

ORTX

Orchard Therapeutics (ORTX)

Orchard Therapeutics PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ORTX
DateHeureSourceTitreSymboleSociété
07/05/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024NASDAQ:ORTXOrchard Therapeutics PLC
03/05/202413h00GlobeNewswire Inc.Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListNASDAQ:ORTXOrchard Therapeutics PLC
20/03/202412h00GlobeNewswire Inc.Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyNASDAQ:ORTXOrchard Therapeutics PLC
18/03/202420h41GlobeNewswire Inc.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.NASDAQ:ORTXOrchard Therapeutics PLC
15/02/202403h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ORTXOrchard Therapeutics PLC
05/02/202420h39Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ORTXOrchard Therapeutics PLC
05/02/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeNASDAQ:ORTXOrchard Therapeutics PLC
02/02/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumNASDAQ:ORTXOrchard Therapeutics PLC
31/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORTXOrchard Therapeutics PLC
25/01/202413h00GlobeNewswire Inc.Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h41Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORTXOrchard Therapeutics PLC
24/01/202411h00GlobeNewswire Inc.Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesNASDAQ:ORTXOrchard Therapeutics PLC
11/12/202313h00GlobeNewswire Inc.Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDNASDAQ:ORTXOrchard Therapeutics PLC
08/12/202322h39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORTXOrchard Therapeutics PLC
30/11/202313h00GlobeNewswire Inc.Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IHNASDAQ:ORTXOrchard Therapeutics PLC
16/11/202322h45Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ORTXOrchard Therapeutics PLC
13/11/202313h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORTXOrchard Therapeutics PLC
13/11/202313h00GlobeNewswire Inc.Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business AccomplishmentsNASDAQ:ORTXOrchard Therapeutics PLC
03/11/202322h11Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:ORTXOrchard Therapeutics PLC
26/10/202313h00GlobeNewswire Inc.Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023NASDAQ:ORTXOrchard Therapeutics PLC
24/10/202313h00GlobeNewswire Inc.Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023NASDAQ:ORTXOrchard Therapeutics PLC
05/10/202323h26Edgar (US Regulatory)Form DEFA14C - Additional information statement materials, definitiveNASDAQ:ORTXOrchard Therapeutics PLC
05/10/202313h19IH Market NewsThursday’s Wall Street Highlights: Orchard Therapeutics, Exxon Mobil, Alphabet, Ford, and moreNASDAQ:ORTXOrchard Therapeutics PLC
05/10/202309h35GlobeNewswire Inc.Kyowa Kirin to Acquire Orchard TherapeuticsNASDAQ:ORTXOrchard Therapeutics PLC
18/09/202313h00GlobeNewswire Inc.Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority ReviewNASDAQ:ORTXOrchard Therapeutics PLC
31/08/202313h00GlobeNewswire Inc.Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023NASDAQ:ORTXOrchard Therapeutics PLC
21/08/202322h32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ORTXOrchard Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ORTX

Dernières Valeurs Consultées

NYSE
MCD
McDonalds
COIN
ETHUSD
Ethereum
EU
VIV
Vivendi
NYSE
KO
Coca Cola
SPI
SP500
S&P 500
EU
CS
Axa
EU
AI
Air Liquide
EU
RNO
Renault
EU
VK
Vallourec
EU
ACA
Credit Agricole
EU
DG
Vinci
EU
GLE
Societe Generale
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés